{"id":"prolonged-cefepime-infusion","safety":{"commonSideEffects":[{"rate":"10-20%","effect":"Nausea"},{"rate":"5-10%","effect":"Vomiting"},{"rate":"5-10%","effect":"Diarrhea"},{"rate":"5-10%","effect":"Headache"},{"rate":"5-10%","effect":"Dizziness"}]},"_chembl":{"chemblId":"CHEMBL186","moleculeType":"Small molecule","molecularWeight":"480.57"},"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"Cefepime works by binding to penicillin-binding proteins (PBPs) located inside the bacterial cell wall, resulting in the disruption of the bacterial cell wall synthesis and ultimately leading to cell lysis and death. This mechanism of action is specific to bacterial cells and does not affect human cells.","oneSentence":"Cefepime is a fourth-generation cephalosporin antibiotic that inhibits bacterial cell wall synthesis.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:30:19.463Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Pneumonia"},{"name":"Urinary tract infections"},{"name":"Skin and soft tissue infections"}]},"trialDetails":[{"nctId":"NCT01484015","phase":"PHASE1","title":"Prolonged or Standard Infusion of Cefepime Hydrochloride in Treating Patients With Febrile Neutropenia","status":"COMPLETED","sponsor":"Wake Forest University Health Sciences","startDate":"2011-02","conditions":"Adult Acute Lymphoblastic Leukemia, Adult Acute Myeloid Leukemia, Adult Burkitt Lymphoma","enrollment":70},{"nctId":"NCT02568800","phase":"PHASE3","title":"Prolonged Infusion Cefepime and Nosocomial Infections","status":"UNKNOWN","sponsor":"Hospital de Clinicas de Porto Alegre","startDate":"2015-10","conditions":"Urinary Tract Infection, Respiratory Tract Infection","enrollment":134}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":1,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Estended Cefepime Infusion"],"phase":"phase_3","status":"active","brandName":"Prolonged Cefepime Infusion","genericName":"Prolonged Cefepime Infusion","companyName":"Hospital de Clinicas de Porto Alegre","companyId":"hospital-de-clinicas-de-porto-alegre","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Cefepime is a fourth-generation cephalosporin antibiotic that inhibits bacterial cell wall synthesis. Used for Pneumonia, Urinary tract infections, Skin and soft tissue infections.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}